Next Article in Journal
Enhanced Intestinal Permeability of Bufalin by a Novel Bufalin-Peptide-Dendrimer Inclusion through Caco-2 Cell Monolayer
Next Article in Special Issue
Design and Synthesis of Malonamide Derivatives as Antibiotics against Methicillin-Resistant Staphylococcus aureus
Previous Article in Journal
Analytical Methods of Phytochemicals from the Genus Gentiana
Previous Article in Special Issue
Synthesis and Antibacterial Activity of Benzo[4,5]isothiazolo[2,3-a]pyrazine-6,6-dioxide Derivatives
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessArticle
Molecules 2017, 22(12), 2096;

In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus

School of Life Science, Handong Global University, Pohang 37554, Korea
Institute of Agricultural Science & Technology, School of Food Science and Biotechnology, Kyungpook National University, Daegu 41566, Korea
LegoChem BioSci. Inc., Daejeon 34302, Korea
These authors contributed equally to this work.
Author to whom correspondence should be addressed.
Received: 10 November 2017 / Revised: 23 November 2017 / Accepted: 28 November 2017 / Published: 29 November 2017
Full-Text   |   PDF [1769 KB, uploaded 30 November 2017]   |  


LCB01-0648 is a novel oxazolidinone compound that shows potent antibacterial activities against most Gram-positive cocci, including the multi-drug resistant Staphylococcus aureus. In this study, in vivo activity of LCB01-0699, a LCB01-0648 prodrug, against S. aureus was evaluated in comparison with that of Linezolid. The results of the systemic infection study demonstrated that LCB01-0699 was more potent than Linezolid against methicillin-susceptible and -resistant S. aureus strains. The in vivo efficacy of LCB01-0699 against methicillin-susceptible and -resistant S. aureus strains in a skin infection model showed more potent activity than Linezolid. LCB01-0699 shows potent in vivo activity against methicillin-susceptible and -resistant S. aureus strains, suggesting that LCB01-0699 would be a novel candidate for the treatment of these infectious diseases caused by S. aureus. View Full-Text
Keywords: LCB01-0699; LCB01-0648; oxazolidinone; in vivo activity; skin infection LCB01-0699; LCB01-0648; oxazolidinone; in vivo activity; skin infection

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Oh, S.-H.; Park, H.-S.; Lee, J.-H.; Baek, S.-Y.; Chae, S.-E.; Oh, K.; Cho, Y.L.; Kwak, J.-H. In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus. Molecules 2017, 22, 2096.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top